Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$214.88 - $256.94 $1.47 Million - $1.76 Million
6,834 Added 132.29%
12,000 $2.64 Million
Q3 2023

Nov 14, 2023

BUY
$211.82 - $248.24 $100,190 - $117,417
473 Added 10.08%
5,166 $1.17 Million
Q2 2023

Aug 14, 2023

BUY
$205.19 - $232.99 $358,056 - $406,567
1,745 Added 59.19%
4,693 $1.04 Million
Q1 2023

May 15, 2023

SELL
$212.99 - $276.17 $11,075 - $14,360
-52 Reduced 1.73%
2,948 $660,000
Q4 2022

Feb 14, 2023

SELL
$205.95 - $280.43 $411,900 - $560,860
-2,000 Reduced 40.0%
3,000 $834,000
Q3 2022

Nov 14, 2022

SELL
$203.3 - $244.17 $304,950 - $366,255
-1,500 Reduced 23.08%
5,000 $1.05 Million
Q2 2022

Aug 15, 2022

SELL
$174.81 - $241.14 $1.42 Million - $1.96 Million
-8,110 Reduced 55.51%
6,500 $1.53 Million
Q1 2022

May 16, 2022

SELL
$166.16 - $213.96 $652,842 - $840,648
-3,929 Reduced 21.19%
14,610 $2.62 Million
Q4 2021

Feb 14, 2022

SELL
$184.32 - $216.08 $38,891 - $45,592
-211 Reduced 1.13%
18,539 $4.01 Million
Q3 2021

Nov 15, 2021

BUY
$179.86 - $214.88 $314,755 - $376,040
1,750 Added 10.29%
18,750 $3.46 Million
Q2 2021

Aug 16, 2021

SELL
$170.47 - $211.93 $184,278 - $229,096
-1,081 Reduced 5.98%
17,000 $3.05 Million
Q1 2021

May 14, 2021

SELL
$153.94 - $174.85 $73,891 - $83,928
-480 Reduced 2.59%
18,081 $3.02 Million
Q4 2020

Feb 16, 2021

SELL
$101.87 - $151.79 $477,566 - $711,591
-4,688 Reduced 20.16%
18,561 $2.82 Million
Q3 2020

Nov 16, 2020

BUY
$99.9 - $121.13 $374,525 - $454,116
3,749 Added 19.23%
23,249 $2.35 Million
Q2 2020

Aug 14, 2020

BUY
$92.74 - $125.82 $247,801 - $336,191
2,672 Added 15.88%
19,500 $2.36 Million
Q1 2020

May 15, 2020

BUY
$79.39 - $115.35 $1.34 Million - $1.94 Million
16,828 New
16,828 $1.6 Million

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.9B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Weiss Multi Strategy Advisers LLC Portfolio

Follow Weiss Multi Strategy Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.